Erasca, Inc. (ERAS) Dividend History

Company News

• Erasca Narrows Loss 46% in Fiscal Q2

  Clinical-stage biotech Erasca reported Q2 2025 results, highlighting reduced operating expenses and progress in two RAS-pathway cancer therapy clinical trials entering Phase 1, while maintaining a strong cash position to fund operations through 2028.

  The Motley Fool
• Erasca to Present at Upcoming Investor Conferences in June

  Erasca, a clinical-stage precision oncology company, announced the advancement of its RAS-targeting franchise, with IND clearance for ERAS-0015 and IND submission for ERAS-4001, both ahead of schedule. The company expects to report Phase 1 monotherapy data for both programs in 2026 and has a projected cash runway of more than 3 years.

  GlobeNewswire Inc.
• Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

  The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.

  Benzinga

  Featured Companies: ALLO CNTX ONCY RXRX
• Should You Buy Erasca, Inc. (ERAS) After Golden Cross?

  Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

  Zacks Investment Research
• 4 Penny Stocks To Watch Before Next Week With Big News

  Penny stocks to watch this week with news. Time to buy or avoid entirely? The post 4 Penny Stocks To Watch Before Next Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: CHPT RKLB VRME